Why Is Psyence Biomedical Stock Trading Lower On Tuesday?

Psyence Biomedical Ltd (NASDAQ:PBM) shares are trading lower on Tuesday by more than 12%, a sharp reversal after a massive rally on Monday. Investors appear to be engaging in profit-taking after the stock’s recent vertical climb.

The stock surged nearly 72.63% during Monday’s regular trading hours. At the time, the psychedelic sector received a major boost.

President Donald Trump signed an executive order to accelerate mental illness treatments. This order specifically targets faster reviews for psychedelic drugs. It also includes a reported $50 million commitment for ibogaine research.

Ibogaine Supply Chain Advantages

Psyence Biomedical stands out due to its GMP-compliant ibogaine platform. Through PsyLabs, the company manages sourcing, extraction, and purification in Africa. Psyence is pitching itself as a rare picks-and-shovels supplier. The company already holds stabilized, pharmaceutical-grade ibogaine doses in its current inventory.

Psyence Technical Analysis

PBM is rebounding from its February low but remains well below its 52-week high. The stock is trading 224.7% above its 20-day simple moving average (SMA) and 130.7% above its 100-day SMA.

The relative strength index (RSI), a momentum gauge, is 96.18.

On a longer lens, the stock is down 43.93% over the past 12 months, which keeps the bigger-picture tape fragile despite the recent surge.

• Key Resistance: $12.50
• Key Support: $10

PBM Stock Price Activity: Psyence Biomedical shares were down 3.54% at $10.90 during premarket trading on Tuesday, according to Benzinga Pro data.

Photo Courtesy: solarseven on Shutterstock.com